Reuters logo
BRIEF-Immunomedics announces publication of cancer drug data
August 21, 2017 / 12:21 PM / in 4 months

BRIEF-Immunomedics announces publication of cancer drug data

Aug 21 (Reuters) - Immunomedics Inc

* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer

* Immunomedics Inc - labetuzumab govitecan was well-tolerated, with a manageable toxicity profile. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below